A hungry nanoparticle that enters your body and eats away at your insides sounds like a nightmare straight out of a Michael Crichton novel. In fact, it could be a future defense against heart attacks, strokes, and potentially other fatal diseases — as strange as that might initially sound.
Developed by scientists at Michigan State and Stanford universities, the innovative new “Trojan Horse” nanoparticle works by munching away portions of the plaques responsible for heart attacks. In a proof-of-concept demonstration, the researchers recently showed that their specially developed nanoparticle is able to accurately home in on atherosclerotic plaque, which is responsible for atherosclerosis, one of the leading causes of death in the United States.
“What the nanotherapy does is it enters inflammatory monocytes [a type of white blood cell] in the blood, and carries them into the plaque — hence the ‘Trojan Horse’ label — where they become macrophages, and stimulatesthose and other macrophages in plaque to devour cellular debris,” Bryan Smith, associate professor of biomedical engineering at MSU, told Digital Trends. “This ‘taking out the trash’ attribute stabilizes the plaque with minimal side effects.”
Nanoparticles that can fight heart attacks already sound potentially revolutionary. But Smith believes they could be used for other applications as well.
“One might ask: Can it treat cancer?” he said. “We think so. However, such other diseases require more speculation. This strategy improves on existing treatments because of its selectivity. The nanoparticle is exquisitely selective toward inflammatory monocytes and macrophages, which allows it to decrease side effects that may be associated with other treatments.”
The work has yet to progress to human trials. So far, the researchers have proven efficacy in a culture dish and in two types of mice that have developed atherosclerosis. They next plan to test large animal models and human tissues, as well as look at how their nanotherapy measures up to other available treatments. They’re also exploring how the nanoparticles could potentially be used as diagnostic imaging tools, highlighting particular cells.
A paper describing the work, titled “Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis,” was recently published in the journal Nature Nanotechnology.
Soon, a mattress protector may be more than a bed cover. Australian medtech company Sleeptite and researchers at RMIT University have received a US patent for FlexiSense, a smart bedding technology that tracks body position and posture to help caregivers identify when older residents may be at risk of falling.
The technology is being developed for Sleeptite’s in-bed monitoring system, REMi, and was recently on display at The MedTech Conference in Boston. A peer-reviewed study in Flexible and Printed Electronics says the sensors can also be made at scale without sacrificing performance or durability.
AI companies spend enormous amounts of time convincing us their technology is safe and secure. But what happens when those same companies become targets of increasingly sophisticated AI-powered attacks? Anthropic, the company behind Claude, is now facing that question. According to a Washington Post report, cybersecurity startup Cathedral discovered vulnerabilities that let its researchers access sensitive information in Anthropic's internal systems.
The researchers used AI agents to identify potential entry points in less than 12 hours. Interestingly, they didn't need to crack Claude itself. Instead, they exploited weaknesses in third-party business applications that Anthropic uses for everyday operations. Anthropic's security testing program disclosed the findings, which allows outside researchers to identify and report vulnerabilities.
Military working dogs charge into places the rest of us would flee. So, I understand why anyone would want to breed tougher, healthier dogs for the job.
Warhound, a new startup from Colossal Biosciences co-founder Ben Lamm and Anduril co-founder Palmer Luckey, has stepped out of stealth with $200 million to clone and gene-edit working dogs for American troops, police departments, and emergency services (via TechCrunch).